COO · NMS · Healthcare
The Cooper Companies, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 34.55
Market price
USD 55.29
Implied upside
-37.5%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 4.4bn | USD 4.7bn | USD 5.1bn | USD 5.4bn | USD 5.8bn | +7.3% |
| EBIT | USD 713.7m | USD 766.1m | USD 822.4m | USD 882.8m | USD 947.6m | +7.3% |
| NOPAT | USD 563.8m | USD 605.2m | USD 649.7m | USD 697.4m | USD 748.6m | +7.3% |
| Add depreciation & amortisation | USD 434.3m | USD 466.2m | USD 500.5m | USD 537.2m | USD 576.7m | +7.3% |
| Less capital expenditure | USD -416.3m | USD -446.9m | USD -479.7m | USD -515.0m | USD -552.8m | +7.3% |
| Less increase in working capital | USD -300.6m | USD -322.7m | USD -346.4m | USD -371.9m | USD -399.2m | +7.3% |
| Free cashflow to firm | USD 281.2m | USD 301.8m | USD 324.0m | USD 347.8m | USD 373.4m | +7.3% |
| Discount factor | 0.9592 | 0.8824 | 0.8118 | 0.7469 | 0.6871 | - |
| Present value | USD 269.7m | USD 266.3m | USD 263.0m | USD 259.8m | USD 256.5m | -1.2% |
| Present Value Of The Forecast | USD 1.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.878 | Reported 0.818, pulled toward 1.0 (Blume) |
| Cost of equity | 9.83% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 10.5bn | 80.8% of capital |
| Total debt | USD 2.5bn | 19.2% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.70% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
86% of EV
- Forecast FCFF, final year
- USD 373.4m
- Capex at depreciation, working capital in reinvestment
- USD 986.4m
- Less reinvestment at g/ROIC (28.7% of NOPAT)
- USD -283.6m
- Capitalised
- USD 702.8m
- ROIC (WACC floor)
- 8.7%
- Terminal value, undiscounted
- USD 11.6bn
- Terminal value, discounted
- USD 8.0bn
- Enterprise value
- USD 9.3bn
- Less net debt
- USD 2.4bn
- Equity value
- USD 6.9bn
Exit at 12.2x EBITDA
91% of EV
- Terminal value, undiscounted
- USD 18.6bn
- Terminal value, discounted
- USD 12.8bn
- Enterprise value
- USD 14.1bn
- Less net debt
- USD 2.4bn
- Equity value
- USD 11.7bn
Spread between methods: 51%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.70% | 50.76 | 51.04 | 51.32 | 51.59 | 51.87 |
| 7.70% | 41.35 | 41.58 | 41.81 | 42.04 | 42.27 |
| 8.70% | 34.16 | 34.36 | 34.55 | 34.74 | 34.94 |
| 9.70% | 28.50 | 28.67 | 28.84 | 29.00 | 29.17 |
| 10.70% | 23.94 | 24.09 | 24.23 | 24.38 | 24.53 |
Outlined: this model. Green text: above today's price of 55.29. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 7.3% | 21.4% | +14.0pp |
| EBIT margin | 16.2% | 24.0% | +7.7pp |
| Discount rate | 8.7% | 6.4% | -2.3pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.